Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical NK Cells and Auto-SCT in Pediatric High-Risk Tumors
NCT02130869Phase 1Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Oct 2014
- Primary completion
- Dec 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of haploidentical natural killer cells in neuroblastoma, lymphoma and solid tumor (3 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Percent of participants with positive ANC engraftment at Day 35. Started Oct 2014; status: completed.
02
Drugs
haploidentical natural killer cells
03
Conditions
neuroblastomalymphomasolid tumor
Beyond the preview
Go deeper on NCT02130869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02130869.